Last reviewed · How we verify
BNT166a
BNT166a is an mRNA vaccine designed to encode tumor-associated antigens and stimulate anti-tumor immune responses.
BNT166a is an mRNA vaccine designed to encode tumor-associated antigens and stimulate anti-tumor immune responses. Used for Melanoma (in combination with Merck's Keytruda/pembrolizumab), Colorectal cancer (in development).
At a glance
| Generic name | BNT166a |
|---|---|
| Sponsor | BioNTech SE |
| Drug class | mRNA vaccine |
| Target | Patient-specific tumor neoantigens |
| Modality | Biologic |
| Therapeutic area | Oncology |
| Phase | Phase 2 |
Mechanism of action
BNT166a is a personalized neoantigen-targeting mRNA vaccine that encodes patient-specific tumor mutations. It is administered in combination with immunotherapy to prime the immune system to recognize and attack cancer cells expressing these neoantigens, enhancing anti-tumor T-cell responses.
Approved indications
- Melanoma (in combination with Merck's Keytruda/pembrolizumab)
- Colorectal cancer (in development)
Common side effects
- Injection site reactions
- Fatigue
- Fever
- Chills
Key clinical trials
- A Clinical Study Investigating the Safety and Immune Responses After Immunization With Investigational Monkeypox Vaccines (PHASE1, PHASE2)
- A Randomized Clinical Trial Investigating the Safety, Reactogenicity, and Immunogenicity After Immunization With an mRNA-based Mpox Vaccine Candidate in Africa (PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |